Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McMaster University

$135,000.00

Modifying Aspergillomarasmine A to Improve Metallo-Beta-Lactamase Inhibition and the Efficacy of Carbapenem Antibiotics

FY 2018-19

Summary
The global spread of antibiotic resistance continues to challenge clinicians and threaten the lives of infected patients. Carbapenem-resistant Enterobacteriaciae (CRE), which include the pathogenic bacteria Escherichia coli and Klebsiella pneumoniae are a major public health concern. This is because of the high mortality rates associated with these bacterial infections and their ability to rapidly spread from person to person. CRE are resistant to last-resort antibiotics known as carbapenems, because they produce metallo-beta-lactamases (MBL) which break these drugs down. Therefore, the development of new countermeasures are sorely needed to mitigate the threat of CRE. A promising solution to this problem is the identification of antibiotic adjuvants, which are non-antibiotic compounds that block antibiotic resistance. An example of one such compound is aspergillomarasmine A (AMA), as it inhibits the activity of MBLs and rescues carbapenems from degradation. The purpose of this study is to better understand the inhibitory activity of AMA so that more potent AMA-related adjuvants can be made. At the Michael G. DeGroote Institute for Infectious Disease Research (IIDR), Dr. Gerry Wright and his group have access to state-of-the art facilities that will facilitate completion of this research. The overall findings of this work will add significant knowledge to the growing body of research on AMA, and the new adjuvants developed will help to overcome this major public health threat in Canada and the rest of the World.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
396979
Name
Sychantha David
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Modifying Aspergillomarasmine A to Improve Metallo-Beta-Lactamase Inhibition and the Efficacy of Carbapenem Antibiotics
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antibiotic Discovery; Antibiotic Resistance; Microbial Chemical Biology
Abstract
The global spread of antibiotic resistance continues to challenge clinicians and threaten the lives of infected patients. Carbapenem-resistant Enterobacteriaciae (CRE), which include the pathogenic bacteria Escherichia coli and Klebsiella pneumoniae are a major public health concern. This is because of the high mortality rates associated with these bacterial infections and their ability to rapidly spread from person to person. CRE are resistant to last-resort antibiotics known as carbapenems, because they produce metallo-beta-lactamases (MBL) which break these drugs down. Therefore, the development of new countermeasures are sorely needed to mitigate the threat of CRE. A promising solution to this problem is the identification of antibiotic adjuvants, which are non-antibiotic compounds that block antibiotic resistance. An example of one such compound is aspergillomarasmine A (AMA), as it inhibits the activity of MBLs and rescues carbapenems from degradation. The purpose of this study is to better understand the inhibitory activity of AMA so that more potent AMA-related adjuvants can be made. At the Michael G. DeGroote Institute for Infectious Disease Research (IIDR), Dr. Gerry Wright and his group have access to state-of-the art facilities that will facilitate completion of this research. The overall findings of this work will add significant knowledge to the growing body of research on AMA, and the new adjuvants developed will help to overcome this major public health threat in Canada and the rest of the World.
Competitiondate
201811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sychantha, David
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~